文献速递膀胱癌与上尿路尿路上皮癌

肿瘤信息循环肿瘤DNA在根治性膀胱切除术前后的可检测性与膀胱癌患者无病生存期的关联

Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2024-07-15

该多中心回顾性分析纳入167例接受根治性膀胱切除术的膀胱癌患者(852份血浆样本),评估肿瘤信息循环肿瘤DNA(ctDNA)在术前、分子残留病灶(MRD)及监测窗口的预后价值。MRD窗口可检测ctDNA与更短无病生存期相关(HR 6.93,p<0.001),监测窗口亦相关(HR 23.02,p<0.001);ctDNA不可检测者未显示从辅助治疗中获益(p=0.34)。

要点

  • MRD窗口可检测ctDNA者无病生存期更短(HR 6.93,p<0.001)。
  • 监测窗口可检测ctDNA者无病生存期更短(HR 23.02,p<0.001)。
  • ctDNA不可检测者未显示从辅助治疗中获益(p=0.34)。

核心结论

  • 在接受根治性膀胱切除术的膀胱癌患者中,ctDNA检测具有预后价值并可能具有预测价值;识别高复发风险患者可能有助于患者咨询和决策。

研究设计与样本

  • 多中心回顾性真实世界数据分析,纳入167例接受根治性膀胱切除术的膀胱癌患者,共852份血浆样本,使用商业化ctDNA检测(Signatera;Natera,Austin,TX,USA)在术前、分子残留病灶(MRD;辅助决策)及监测窗口进行检测。

主要发现

  • 在术后MRD窗口,可检测ctDNA与不可检测ctDNA相比,无病生存期更短(HR 6.93;p<0.001)。
  • 在监测窗口,可检测ctDNA与不可检测ctDNA相比,无病生存期更短(HR 23.02;p<0.001)。
  • ctDNA不可检测的患者未显示从辅助治疗中获益(p=0.34)。
  • 术前(p=0.045)、MRD(p=0.002)和监测(p<0.001)窗口可检测ctDNA是与更短无病生存期独立相关的唯一危险因素。

临床怎么用

  • 作者认为,ctDNA检测具有预后价值并可能具有预测价值,识别高复发风险患者可能有助于患者咨询和决策。

局限性

  • 局限性包括研究的回顾性和非随机性质。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Despite curative-intent radical cystectomy (RC), patients with muscle-invasive bladder cancer (MIBC) are at high risk of recurrence. Biomarkers are urgently needed to refine prognostication and selection of appropriate perioperative systemic therapies. Our aim was to evaluate the prognostic and predictive value of tumor-informed circulating tumor DNA (ctDNA) results in a multicenter cohort of patients with bladder cancer who underwent RC. METHODS: We performed a retrospective analysis of real-world data for a commercial ctDNA test (Signatera; Natera, Austin, TX, USA) performed in 167 patients (852 plasma samples) before RC and during molecular residual disease (MRD; adjuvant decision) and surveillance windows. We assessed the correlation between recurrence and ctDNA status before and after RC using Cox regression analysis. RESULTS AND LIMITATIONS: During study-defined postoperative MRD and surveillance windows, detectable ctDNA was associated with shorter disease-free survival (DFS) when compared to undetectable ctDNA (MRD: hazard ratio 6.93; p < 0.001; surveillance: hazard ratio 23.02; p < 0.001). Of note, patients with undetectable ctDNA did not appear to benefit from adjuvant therapy (p = 0.34). Detectable ctDNA in the pre-RC (p = 0.045), MRD (p = 0.002), and surveillance (p < 0.001) windows was the only risk factor independently associated with shorter DFS. Limitations include the retrospective and nonrandomized nature of the study. CONCLUSIONS: ctDNA testing in patients with bladder cancer undergoing RC was prognostic and potentially predictive. Identification of patients at high risk of recurrence may aid in patient counseling and decision-making. PATIENT SUMMARY: We found that outcomes for patients with muscle-invasive bladder cancer are strongly linked to detection of tumor DNA in blood samples. The results show the value of tumor-informed testing for tumor DNA in blood for decisions on the best treatment for each individual patient.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Sfakianos JP, Basu A, Laliotis G, et al. Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer. Eur Urol Oncol. 2024. PMID: 39013741. doi:10.1016/j.euo.2024.07.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。